Skip to main content
Erschienen in: World Journal of Surgery 9/2009

01.09.2009

Metastasis-Associated Protein 1 (MTA1) Overexpression is Closely Associated with Shorter Disease-Free Interval After Complete Resection of Histologically Node-Negative Esophageal Cancer

verfasst von: Shu-Hai Li, Zhou Wang, Xiang-Yan Liu

Erschienen in: World Journal of Surgery | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of the present study was to investigate the expression of metastasis-associated protein 1 (MTA1) and its relationship to the disease-free interval after resection of pathologic N0 (pN0) esophageal squamous cell cancer (ESCC).

Methods

The subjects were 90 patients who successfully underwent complete resection of pN0 ESCC between May 2001 and May 2003. Immunohistochemical staining for MTA1 protein was performed using the avidin–biotin peroxidase complex method. Log-rank test was performed to compare the disease-free interval, and Cox regression multivariate analysis was performed to judge independent prognostic factors.

Results

Metastasis-associated protein 1 overexpression was detected in 40 esophageal cancer tissues. Disease-free interval was significantly associated with MTA1 protein overexpression (p = 0.015). The overall 5-year survival rate was 45.6%, the 5-year survival rate of patients with MTA1 protein overexpression was significantly lower than that of those without overexpression (25.0 versus 62.0%; p < 0.001). The results of multivariate analysis confirmed that T status and MTA1 protein overexpression were independent prognostic factors.

Conclusions

Metastasis-associated protein 1 overexpression was detected in pN0 ESCC and was significantly correlated with shorter disease-free interval. T status and MTA1 protein overexpression were both independent prognostic factors. These findings suggested MTA1 might be a predictor of relapsing phenotype and a prognostic factor in esophageal cancer.
Literatur
1.
Zurück zum Zitat Japanese Society of Esophageal Diseases (2005) Long-term results of esophagectomy for esophageal cancer in Japan, 1988–1997. Esophagus 2:1–13CrossRef Japanese Society of Esophageal Diseases (2005) Long-term results of esophagectomy for esophageal cancer in Japan, 1988–1997. Esophagus 2:1–13CrossRef
2.
Zurück zum Zitat Korst RJ, Rusch VW, Venkatraman E et al (1998) Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 115:660–670PubMedCrossRef Korst RJ, Rusch VW, Venkatraman E et al (1998) Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 115:660–670PubMedCrossRef
3.
Zurück zum Zitat Visbal AL, Allen MS, Miller DL et al (2001) Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 71:1803–1808PubMedCrossRef Visbal AL, Allen MS, Miller DL et al (2001) Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 71:1803–1808PubMedCrossRef
4.
Zurück zum Zitat Rice TW, Blackstone EH, Adelstein DJ et al (2001) N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 121:454–464PubMedCrossRef Rice TW, Blackstone EH, Adelstein DJ et al (2001) N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 121:454–464PubMedCrossRef
5.
Zurück zum Zitat Eloubeidi MA, Desmond R, Arguedas MR et al (2002) Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 95:1434–1443PubMedCrossRef Eloubeidi MA, Desmond R, Arguedas MR et al (2002) Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 95:1434–1443PubMedCrossRef
6.
Zurück zum Zitat Toh Y, Pencil SD, Nicolson GL (1994) A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269:22958–22963PubMed Toh Y, Pencil SD, Nicolson GL (1994) A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 269:22958–22963PubMed
7.
Zurück zum Zitat Toh Y, Pencil SD, Nicolson GL (1995) Analysis of the complete sequence of the novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma and breast cancer cell lines. Gene 159:97–104PubMedCrossRef Toh Y, Pencil SD, Nicolson GL (1995) Analysis of the complete sequence of the novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma and breast cancer cell lines. Gene 159:97–104PubMedCrossRef
8.
Zurück zum Zitat Nicolson GL, Nawa A, Toh Y et al (2003) Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer invasion, proliferation and nuclear regulation. Clin Exp Metastasis 20:19–24PubMedCrossRef Nicolson GL, Nawa A, Toh Y et al (2003) Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer invasion, proliferation and nuclear regulation. Clin Exp Metastasis 20:19–24PubMedCrossRef
9.
Zurück zum Zitat Kumar R, Wang RA, Bagheri-Yarmand R (2003) Emerging roles of MTA family members in human cancers. Semin Oncol 30:30–37PubMedCrossRef Kumar R, Wang RA, Bagheri-Yarmand R (2003) Emerging roles of MTA family members in human cancers. Semin Oncol 30:30–37PubMedCrossRef
10.
Zurück zum Zitat Mazumdar A, Wang RA, Mishra SK et al (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30–37PubMedCrossRef Mazumdar A, Wang RA, Mishra SK et al (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30–37PubMedCrossRef
11.
Zurück zum Zitat Yan C, Wang H, Toh Y et al (2003) Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem 278:2309–2316PubMedCrossRef Yan C, Wang H, Toh Y et al (2003) Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem 278:2309–2316PubMedCrossRef
12.
Zurück zum Zitat Jang KS, Paik SS, Chung H et al (2006) MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer. Cancer Sci 97:374–379PubMedCrossRef Jang KS, Paik SS, Chung H et al (2006) MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer. Cancer Sci 97:374–379PubMedCrossRef
13.
Zurück zum Zitat Martin MD, Hilsenbeck SG, Mohsin SK et al (2006) Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95:7–12PubMedCrossRef Martin MD, Hilsenbeck SG, Mohsin SK et al (2006) Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95:7–12PubMedCrossRef
14.
Zurück zum Zitat Hofer MD, Kuefer R, Varambally S et al (2004) The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 64:825–829PubMedCrossRef Hofer MD, Kuefer R, Varambally S et al (2004) The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 64:825–829PubMedCrossRef
15.
Zurück zum Zitat Balasenthil S, Broaddus RR, Kumar R (2006) Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol 37:656–661PubMedCrossRef Balasenthil S, Broaddus RR, Kumar R (2006) Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol 37:656–661PubMedCrossRef
16.
Zurück zum Zitat Ryu SH, Chung YH, Lee H et al (2008) Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 47:929–936PubMedCrossRef Ryu SH, Chung YH, Lee H et al (2008) Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 47:929–936PubMedCrossRef
17.
Zurück zum Zitat Mahoney MG, Simpson A, Jost M et al (2002) Metastasis-associated protein (MTA) 1 enhances migration, invasion and anchorage-independent survival of immortalized human keratinocytes. Oncogene 21:2161–2170PubMedCrossRef Mahoney MG, Simpson A, Jost M et al (2002) Metastasis-associated protein (MTA) 1 enhances migration, invasion and anchorage-independent survival of immortalized human keratinocytes. Oncogene 21:2161–2170PubMedCrossRef
18.
Zurück zum Zitat Hofer MD, Menke A, Genze F et al (2004) Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer 90:455–462PubMedCrossRef Hofer MD, Menke A, Genze F et al (2004) Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer 90:455–462PubMedCrossRef
19.
Zurück zum Zitat Toh Y, Ohga T, Endo K et al (2004) Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110:362–367PubMedCrossRef Toh Y, Ohga T, Endo K et al (2004) Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110:362–367PubMedCrossRef
20.
Zurück zum Zitat Chen G, Wang Z, Liu XY et al (2007) Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor Lewis esophagectomy. World J Surg 31:1107–1114PubMed Chen G, Wang Z, Liu XY et al (2007) Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor Lewis esophagectomy. World J Surg 31:1107–1114PubMed
21.
Zurück zum Zitat Nawa A, Nishimori K, Lin P et al (2000) Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. J Cell Biochem 79:202–212PubMedCrossRef Nawa A, Nishimori K, Lin P et al (2000) Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. J Cell Biochem 79:202–212PubMedCrossRef
22.
Zurück zum Zitat Li SH, Wang Z, Liu XY et al (2007) Lymph node micrometastasis: a predictor of early tumor relapse after complete resection of histologically node-negative esophageal cancer. Surg Today 37:1047–1052PubMedCrossRef Li SH, Wang Z, Liu XY et al (2007) Lymph node micrometastasis: a predictor of early tumor relapse after complete resection of histologically node-negative esophageal cancer. Surg Today 37:1047–1052PubMedCrossRef
23.
24.
Zurück zum Zitat Raja S, Luketich JD, Kelly LA et al (2002) Rapid, quantitative reverse transcriptase-polymerase chain reaction: application to intraoperative molecular detection of occult metastases in esophageal cancer. J Thorac Cardiovasc Surg 123:475–482PubMedCrossRef Raja S, Luketich JD, Kelly LA et al (2002) Rapid, quantitative reverse transcriptase-polymerase chain reaction: application to intraoperative molecular detection of occult metastases in esophageal cancer. J Thorac Cardiovasc Surg 123:475–482PubMedCrossRef
Metadaten
Titel
Metastasis-Associated Protein 1 (MTA1) Overexpression is Closely Associated with Shorter Disease-Free Interval After Complete Resection of Histologically Node-Negative Esophageal Cancer
verfasst von
Shu-Hai Li
Zhou Wang
Xiang-Yan Liu
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 9/2009
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-009-0119-y

Weitere Artikel der Ausgabe 9/2009

World Journal of Surgery 9/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.